HER2-Positive Breast Cancer – Epidemiology Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The burden of diagnosed HER2+/HR+ breast cancer is expected to increase at an annual growth rate (AGR) of 1.70% from around 100,000 cases in 2020 to 114,000 cases in 2030 in the eight major markets (8MM*). This report reveals that the increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets.

PR13956 2.png

HER2-positive breast cancer consists of HER2+/HR+ and HER2+/HR- subtypes. In the 8MM, HER2+/HR+ was the most common subtype of HER2-positive breast cancer, followed by HER2+/HR- breast cancer.

Bishal Bhandari, PhD, Senior Epidemiologist at GlobalData, comments: “Although HER2+/HR+ was the most common type, GlobalData’s research shows that cases of HER2+/HR- breast cancer are also growing steadily in the 8MM. This is important as HER2-positive cancer overall is more aggressive than HER2-negative cancer.”

In the 8MM, according to GlobalData epidemiologists, the majority of diagnosed incident cases of HER2-positive cases were in stage I–III, and fewer than 10% of cases were in stage IV in 2020.

Bhandari adds: “It is promising development that the majority of breast cancer cases are now diagnosed at earlier stages, which improves breast cancer survival and response to treatment. However, due to a longer life expectancy in breast cancer patients, the overall number of individuals with breast cancer will continue to increase over time.”

*8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and urban China

Scope

  • HER2-Positive Breast Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of HER2-positive in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 8MM: diagnosed incident cases of all invasive, HER2+/HR+, and HER2+/HR- breast cancer; diagnosed five-year prevalent cases of HER2+/HR+, and HER2+/HR- breast cancer; and diagnosed incident cases of HER2+/HR+ and HER2+/HR- breast cancer by cancer staging. Additionally, diagnosed incident cases of HER2+HR+ and HER2+/HR- breast cancer cases are further segmented by metastasis, and biomarker expression. HER2+/HR+ and HER2+/HR- breast cancer cases are also segmented by menopausal status.
  • The HER2-Positive Epidemiology Report and Model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Highlights

  • Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all incident cases of female cancers, making the disease exceedingly prevalent. Breast cancer is classified based on human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status (American Cancer Society, 2019). HER2-/HR+ and HER2-/HR- were analyzed in the HER2-negative breast cancer report. This report explores HER2-positive breast cancer, namely, HER2+/HR+ and HER2+/HR- breast cancer.
  • GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HER2-positive breast cancer. GlobalData epidemiologists applied country-specific incidence rates of HER2-positive breast cancer wherever available, to each country’s population to obtain the number of estimated diagnosed incident cases.
  • The following data describes epidemiology of HER2+/HR+ and HER2+/HR- cases. In 2020, the 8MM had 97,308 diagnosed incident cases of HER2/HR+ breast cancer. This is expected to increase to 113,608 diagnosed incident cases by 2030, at an Annual Growth Rate (AGR) of 1.68%. In the 8MM, the diagnosed incident cases of HER2+/HR- breast cancer will increase from 53,824 cases in 2020 to 63,106 cases in 2030, at an AGR of 1.72%. This increase is partly attributed to the moderately rising trend in historical incidence in the 8MM, combined with underlying demographic changes in the respective markets. The early diagnosis and development of more effective therapies would improve survival from HER2-positive breast cancer.

Reasons to Buy

The HER2-Positive Breast Cancer Epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global HER2-positive breast cancer market.
  • Quantify patient populations in the global HER2-positive market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the HER2-positive cancer stages that present the best opportunities for HER2- positive therapeutics in each of the markets covered.
  • Understand magnitude of HER2-positive breast cancer market by biomarkers.

Table of Contents

Table of Contents

| About GlobalData

1 HER2-Positive Breast Cancer: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 Forecast Methodology

2.4.1 Sources Used

2.4.2 Forecast Assumptions and Methods

2.5 Epidemiological Forecast for All Invasive and HER2-Positive Breast Cancer (2020-2030)

2.5.1 Diagnosed Incident Cases of All Invasive Breast Cancer

2.5.2 Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer

2.5.3 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer

2.5.4 Diagnosed Incident Cases of HER2+/HR- Breast Cancer

2.5.5 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stages

2.5.6 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stages

2.5.7 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status

2.5.8 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status

2.5.9 Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression

2.5.10 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression

2.5.11 Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression

2.5.12 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis

2.5.13 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis

2.5.14 Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression

2.5.15 Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of Analysis

2.6.4 Strengths of Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

3.3 Contact Us

Table

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for All Invasive HER2-Positive Breast Cancer

Figures

Figure 1: 8MM, Diagnosed Incident Cases of HER2+/HR+ Breast Cancer, Women, N, Ages ≥18 Years, 2020 and 2030

Figure 2: 8MM, Diagnosed Incident Cases of HER2+/HR- Breast Cancer, Women, N, Ages ≥18 Years, 2020 and 2030

Figure 3 : 8MM, Diagnosed Incidence of HER2+/HR+ Breast Cancer, Ages ≥18 Years, Women, Cases per 100,000 Population, 2010‒2030

Figure 4: 8MM, Diagnosed Incidence of HER2+/HR- Breast Cancer, Ages ≥18 Years, Women, Cases per 100,000 Population, 2010‒2030

Figure 5: 8MM, Sources Used and Not Used for Diagnosed Incident Cases of All Invasive Breast Cancer

Figure 6: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer

Figure 7: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Stage

Figure 8: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Menopausal Status

Figure 9: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by PD-1 and PD-L1 Expression

Figure 10: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Ki67, NTRK, and RET Expression

Figure 11: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Bone and Brain Metastasis

Figure 12: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by IHC3+ Expression

Figure 13: 8MM, Sources Used for Five-Year Diagnosed Prevalent Cases of HER2+/HR+ and HER2+/HR- Breast Cancer

Figure 14: 8MM, Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages ≥18 Years, N, 2020

Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages ≥18 Years, N, 2020

Figure 16: 8MM, Diagnosed Incident Cases of HER2+/HR+ Breast Cancer, Women, Ages ≥18 Years, N, 2020

Figure 17: 8MM, Diagnosed Incident Cases of HER2+/HR- Breast Cancer, Women, Ages ≥18 Years, N, 2020

Figure 18: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stage, Women, Ages ≥18 Years, N, 2020

Figure 19: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stage, Women, Ages ≥18 Years, N, 2020

Figure 20: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status, Women, Ages ≥18 Years, %, 2020

Figure 21: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status, Women, Ages ≥18 Years, %, 2020

Figure 22: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression, Women, Ages ≥18 Years, N, 2020

Figure 23: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression, Women, Ages ≥18 Years, N, 2020

Figure 24: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression, Women, Ages ≥18 Years, N, 2020

Figure 25: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis, Women, Ages ≥18 Years, N, 2020

Figure 26: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis, Women, Ages ≥18 Years, N, 2020

Figure 27: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression, Women, Ages ≥18 Years, N, 2020

Figure 28: 8MM, Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer, Women, Ages ≥18 Years, N, 2020

Frequently asked questions

HER2-Positive Breast Cancer – Epidemiology Forecast to 2030 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

HER2-Positive Breast Cancer – Epidemiology Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at HER2-Positive Breast Cancer – Epidemiology Forecast to 2030 in real time.

  • Access a live HER2-Positive Breast Cancer – Epidemiology Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.